ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate if ME-401 can improve the treatment of patients with
diffuse large b-celllymphoma (DLBCL). Many patients with DLBCL that are treated with the
standard of care (R-CHOP) are cured. However, a little less than half of patients will have
their cancer come back despite being treated. Once DLBCL comes back, it is much harder to
treat and treatment is much more aggressive. This study will combine ME-401 with R-CHOP.
There are 2 parts to this study: part1 referred to as phase I and part 2 referred to as phase
2. The goal of the phase I study is to find the safest dose to give patients in combination
with R-CHOP. The goal of the phase 2 study is to use the safest dose (found in phase 1) in
combination with R-CHOP to see if it decreases the rate of cancer coming back after it is
treated.